Palmitoylethanolamide (PEA) (544-31-0) Manufacturer - Cofttek

Palmitoylethanolamide (PEA) (544-31-0)

April 7, 2020

Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent and one also found in foods such as eggs and milk, no serious side effects or drug–drug interactions been identified.

 


Status: In Mass Production
Unit: 25kg/Drum

Palmitoylethanolamide (PEA) (544-31-0) video

 

Palmitoylethanolamide (PEA) Specifications

 

Name: Palmitoylethanolamide (PEA)
CAS: 544-31-0
Purity 98% Micronized PEA;98% powder
Molecular Formula: C18H37NO2
Molecular Weight: 299.49 g/mol
Melt Point: 93 to 98 °C
Chemical name: Hydroxyethylpalmitamide Palmidrol N-Palmitoylethanolamine Palmitylethanolamide
Synonyms: Palmitoylethanolamide

Palmidrol

N-(2-Hydroxyethyl)hexadecanamide

N-palmitoylethanolamine

InChI Key: HXYVTAGFYLMHSO-UHFFFAOYSA-N
Half Life: 8 hours
Solubility: Soluble in DMSO, Methanol, Water
Storage Condition: 0 – 4 C for short term (days to weeks), or -20 C for long term (months)
Application: Palmitoylethanolamide (PEA) belong to endocannabinoid family, a group of fatty acid amides. PEA has been proven to have analgesic and anti-inflammatory activity and has been used in several controlled studies focused on the management of chronic pain among adult patients with different underlying clinical conditions.
Appearance: White powder

 

What is Palmitoylethanolamide (544-31-0)?

Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent and one also found in foods such as eggs and milk, no serious side effects or drug–drug interactions been identified. PEA has demonstrated effectiveness for chronic pain of multiple types associated with many painful conditions, especially with neuropathic (nerve) pain, inflammatory pain and visceral pain such as endometriosis and interstitial cystitis.

 

Palmitoylethanolamide (544-31-0) benefits

At first, it reduces, via the peroxisome proliferator-activated receptor alpha (PPARα), the recruitment and activation of mast cells at sites of nerve injury and the release of pro-inflammatory mediators from these cells; secondly, it inhibits the microglia activation and the recruitment of mast cells into spinal cord after peripheral nerve injury, as well as following spinal neuroinflammation or spinal cord injury.

Several studies focused on the use of PEA in a multitude of chronic pain conditions. For example, it can have a beneficial effect like adjuvant for the treatment of the low back pain or it was used alone for chronic pain management in critically ill older patients, where the use of traditional analgesics can lead to high risk of adverse effect. Encouraging results have been shown in the treatment of non-surgical radiculopathies with an ultra-micronized formulation of PEA and the combination therapy with alpha-lipoic acid to reduce chronic prostatitis/chronic pelvic pain syndrome.

 

Palmitoylethanolamide (544-31-0) Mechanism Of Action?

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, an analog of the endocannabinoid anandamide (AEA), that belongs to the family of N-acylethanolamines (NAE). NAEs are released from cells in response to noxious stimuli. As all NAEs, also the PEA has a local effect, and its tissue levels are closely regulated through the balance of production and degradation activity. Two intracellular amidases, expressed in the inflammatory cells, have been involved in lipid amide degradation: fatty-acid amide hydrolase (FAAH) and N-acylethanolamine hydrolyzing acid amidase (NAAA).

 

Palmitoylethanolamide (544-31-0) Application

Palmitoylethanolamide (PEA) belong to endocannabinoid family, a group of fatty acid amides. PEA has been proven to have analgesic and anti-inflammatory activity and has been used in several controlled studies focused on the management of chronic pain among adult patients with different underlying clinical conditions.

 

Palmitoylethanolamide (PEA) powder for sale(Where to Buy Palmitoylethanolamide (PEA) powder in bulk)

Our company enjoys long term relationships with our clients because we focus on customer service and providing great products. If you are interested in our product, we are flexible with the customization of orders to suit your specific need and our quick lead time on orders guarantees you’ll have great tasting our product on-time. We also focus on value-added services. We are available for service questions and information to support your business.

We are an professional Palmitoylethanolamide (PEA) powder supplier for several years, we supply products with competitive price, and our product is of the highest quality and undergoes strict, independent testing to ensure that it is safe for consumption around the world.

 

References

  • Hansen HS. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol. 2010;224(1):48–55
  • Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie. 2010;92(6):724–7
  • Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Vet Immunol Immunopathol. 2010;133(1):9–15
  • Palmitoylethanolamide (PEA): Benefits, Dosage, Uses, Supplement